Gatifloxacin mesylate is a fourth generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity. It is able to inhibit bacterial type II topoisomerase (IC50 = 13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA rotamase (IC50 = 0.109 μg/ml). It can be used to treat bacterial conjunctivitis in vivo, and its injection can treat acute urinary tract infections with efficacy comparable to levofloxacin hydrochloride injection[1].
Gatifloxacin mesylate (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis[4].
| Animal Model: | Female BALB/c mice with Nocardia brasiliensis in the right hind footpad.
|
| Dosage: | 100 mg/kg |
| Administration: | Subcutaneous injection; 3 times a day; 30 days |
| Result: | Reduced the production of lesions in mice. |
Quinolone; Topoisomerase II: 36.7 μM (IC50)
[1] L. DENG. Observation on the curative effect of gatifloxacin mesylate injection in the treatment of acute urinary tract infections[J]. 国际医药卫生导报, 2009. DOI:10.3760/CMA.J.ISSN.1007-1245.2009.05.025.
